GHK-Cu: Does It Have Side Effects or Is It Completely Safe?

The tripeptide GHK-Cu (glycyl-L-histidyl-L-lysine copper) has gained attention in dermatology and regenerative medicine for its reported effects on skin, hair, and wound healing.

Before considering prolonged use, it is worth separating what has actually been tested from what has not — the answer differs sharply between a cosmetic serum and an injection.

What is GHK-Cu and How Does It Work on Hair?

GHK-Cu is a tripeptide that binds copper and is naturally found in human plasma, saliva, and urine. Its concentration falls with age, which prompted research into its role in cell regeneration, collagen production, and oxidative stress.

In the context of hair, laboratory work has looked at whether it stimulates cell proliferation in follicles, reduces scalp inflammation, and improves hair anchoring. It has also been examined for a possible influence on the anagen phase of the hair cycle. These are cell-culture and animal findings; no completed human trial has measured what GHK-Cu does to hair count or shedding in people.

Does GHK-Cu Have Side Effects? Here's What the Evidence Shows

Claims that GHK-Cu "is safe" are common online. Safety, though, is specific to a route, a concentration and a duration of use — and for GHK-Cu those three things have only been studied for one route.

Topical Use: What You May Feel on Your Scalp

GHK-Cu is most commonly sold in cosmetic creams, serums, and lotions, typically at around 0.05%–0.1%. At those cosmetic concentrations, reported reactions in the published literature and in product reporting have been local and uncommon:

Mild irritation: redness, itching, or a burning sensation when applying products containing GHK-Cu.

Increased sensitivity: some scalps react with initial dryness or flaking.

Allergic reactions: although reported as rare, they may occur in people sensitive to peptides or to copper.

The evidence behind that picture is laboratory evidence, not clinical-trial evidence. A 2016 Scientific Reports study by Li and colleagues tested copper compounds on cultured human keratinocytes and found that GHK-Cu was not cytotoxic and did not significantly change skin-irritation biomarkers, while copper chloride and copper acetate did at the same concentrations. That is a cell model with a 24-hour exposure. There is no published clinical trial characterising topical GHK-Cu's side-effect profile on human scalp over months of use.

Injectable Use: Is It Really a Safe Option?

Injectable GHK-Cu is not an approved medicine and has not been tested for safety in a published human trial. The FDA has placed GHK-Cu on its list of bulk drug substances that may present significant safety risks when used in compounding.

Reports circulating in user communities — not from controlled studies — include dizziness and fatigue, mild nausea, and changes in blood pressure. Because the peptide is discussed as affecting circulation, blood-pressure change is the effect most often reported, and it is the one that should not be treated as a minor inconvenience.

Stop using it and seek medical advice if you experience dizziness, fainting, palpitations, breathing difficulty, a marked change in blood pressure, or any swelling, spreading redness, pain or fever at an injection site. An unapproved, non-sterile injectable also carries infection and contamination risk that a topical serum does not.

No extensive clinical study in humans has evaluated the long-term safety of injected GHK-Cu, at any dose.

Oral Use: What We Know So Far

GHK-Cu in supplement form has been minimally studied in humans. Benefits similar to topical use are theorised, but bioavailability is uncertain. The absence of documented severe adverse effects reflects the absence of studies rather than a demonstrated safety record.

GHK-Cu as a Treatment: What to Expect Based on Its Use

Primary Treatment: Can It Be Effective on Its Own?

No published human trial has tested GHK-Cu as a standalone hair-loss treatment, so no outcome can be promised. Users of cosmetic peptide serums commonly report gradual changes in skin texture and scalp comfort; increased hair density is not an outcome any trial has demonstrated for GHK-Cu, and it should not be expected from the peptide alone.

Whatever effect it has would depend on individual factors such as genetics and the underlying cause of hair loss.

GHK-Cu is not a cure and not a one-size-fits-all solution. Nothing about its described mechanism addresses the DHT sensitivity that drives androgenetic alopecia, which is why clinicians and community users alike treat it as an addition to, not a substitute for, treatments with published trials behind them.

Some people also report an initial adjustment phase with temporary sensitivity or mild irritation when starting any new topical.

As a Complementary Treatment: Enhancing Other Therapies

GHK-Cu is more often discussed as an addition to other treatments than as a standalone one — alongside microneedling, fractional laser, and topical therapies with retinoids or growth factors.

Aesthetic clinics commonly use copper peptides for post-procedure recovery, and review articles describe effects on skin regeneration, inflammation and collagen synthesis in laboratory models. Whether adding GHK-Cu improves the result of any of these procedures has not been tested in a published trial. In the first few days some users report increased scalp sensitivity with mild flaking or redness, especially alongside chemical exfoliants or abrasive techniques.

User reviews on retail platforms and dermatology forums are frequently cited for GHK-Cu serums. These are customer impressions, not evidence: they are unverified, often incentivised, and cannot separate the peptide from everything else in the formulation or the routine. Some users report firmer-looking skin when combining it with vitamin C or hyaluronic acid; others report irritation when mixing it with strong acids.

Key Research on the Safety of GHK-Cu

The research base on GHK-Cu safety is small and almost entirely preclinical.

The 2016 Scientific Reports study described above (Li et al., Sci Rep 2016;6:37664) is the most directly relevant safety work: a keratinocyte-based model comparing GHK-Cu with copper chloride and copper acetate at 58 and 580 µM over 24 hours. GHK-Cu was not cytotoxic and did not raise skin-irritation biomarkers; the authors concluded it has a low potential to induce skin irritation. Being a cell study, it cannot be extrapolated to prolonged use on human skin, and it says nothing about injection.

Pickart and Margolina's 2018 review (International Journal of Molecular Sciences) surveyed preclinical work on GHK-Cu's regenerative effects and reported tissue-repair and antioxidant activity with no adverse effects noted. It is a review of preclinical studies by the peptide's discoverer, not an independent clinical safety assessment, and the absence of extensive clinical trials limits what can be said about prolonged treatment or vulnerable populations.

The FDA has stated that GHK-Cu lacks sufficient evidence to support injectable use and has listed it among bulk substances that may present significant safety risks in compounding. That is the clearest regulatory signal available, and it applies specifically to compounded and injectable forms.

User experience

Community discussions on GHK-Cu and its side effects suggest users generally find topical use well tolerated, while questions about its mechanism and effectiveness remain open. One user asserted that GHK-Cu is a potent inhibitor of type 1 5-alpha reductase in hair follicles, and speculated that it could reduce hair loss without the side effects associated with type 2 inhibitors such as finasteride. No published human study supports that, and swapping a prescription drug for an unapproved peptide is a decision for a prescriber, not a forum.

Another discussion covered mixing GHK-Cu into RU58841, an unapproved topical anti-androgen. Home-mixing an unapproved peptide into an unapproved research chemical is not a regulated treatment: concentration, sterility, stability and skin absorption are all unknown, and this article does not describe how it is done.

A thread on the Maneup GHK-Cu hair growth serum showed scepticism about its effectiveness, and concern about DIY injections of GHK-Cu, with mixed reports across topical and injectable use.

While community reports of serious side effects are uncommon, that is not the same as an established safety record, and it says nothing about long-term or injected use.

Conclusion: Is GHK-Cu Safe?

For topical cosmetic use, GHK-Cu has behaved benignly in the laboratory work that exists, and reported reactions are local and uncommon — mild irritation, sensitivity, or flaking, particularly alongside other active ingredients. That is the strongest statement the evidence supports, and it is not the same as a demonstrated clinical safety record.

For injectable and oral use the evidence is not merely limited but effectively absent, and the FDA has not approved these forms and has flagged the substance for compounding risk.

GHK-Cu remains an experimental compound for hair loss: it is not an approved medicine for any hair condition, no trial has measured its effect on hair in people, and its long-term safety is unknown. Talk to a doctor or pharmacist before starting, stopping or combining GHK-Cu with any hair-loss treatment, and before using any injected or compounded preparation.

References

Li, H., Toh, P. Z., Tan, J. Y., Zin, M. T., Lee, C. Y., Li, B., Leolukman, M., Bao, H., & Kang, L. (2016). Selected biomarkers revealed potential skin toxicity caused by certain copper compounds. Scientific Reports, 6, 37664. https://pubmed.ncbi.nlm.nih.gov/27892491/

Pickart, L., & Margolina, A. (2018). Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences, 19(7), 1987. https://doi.org/10.3390/ijms19071987

FDA. (2024). Substances in Compounding that May Present Significant Safety Risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks

FDA. (2024). 503A Categories Update for September 2024. https://www.fda.gov/media/94155/download

Tressless. (2024, January 24). GHK-Cu is a potent 5-AR inhibitor? Retrieved from https://reddit.com/r/tressless/comments/19ecz4n/ghkcu_is_potent_5ar_inhibitor/

Tressless. (2024, November 25). Simple to add GHK-Cu to RU58841? Retrieved from https://reddit.com/r/tressless/comments/1gzbej7/simple_to_add_ghkcu_to_ru58841/

Tressless. (2024, May 2). Does it work? Maneup GHK-Cu hair growth serum. Retrieved from https://reddit.com/r/tressless/comments/1cieesf/does_it_work_maneup_ghkcu_hair_growth_serum/